NMNoe Macias-Segura

Noe Macias-Segura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noe Macias-Segura has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of putative miRNA biomarkers in early rheumatoid arthritis by genome-wide microarray profiling: A pilot study

    by M.F. Romo-García, Y. Bastian, M. Zapata-Zuñiga, N. Macías-Segura, J.D. Castillo-Ortiz, E.E. Lara-Ramírez, J.C. Fernández-Ruiz, A.J. Berlanga-Taylor, R. González-Amaro, C. Ramos-Remus, et al.


  • Open Access

    Gene expression profile and cytokine analysis in experimental autoimmune encephalomyelitis (EAE) in AVP deficient rats

    by Andres Quintanar‐Stephano, Verónica Viñuela‐Berni, Noe Macías‐Segura, Fernando Valdez‐Urias, Kalman Kovacs

    Introduction: Human Multiple Sclerosis (MS) is a medically important disease. MS and its experimental autoimmune encephalomyelitis (EAE) paradigm are central nervous system demyelinizing diseases in which the immune system is directly involved. The pursuit for new treatments for MS still as an important goal for research. The use of the EAE animals to study the immune mechanisms that mediate the disease still being the best strategy to deep into the immune‐neuroendocrine interactions during the pathogenesis. Previously we have demonstrated that neurointermediate pituitary lobectomy (NIL) decreases humoral and cell‐mediated immune responses and that AVP is directly involved. Nevertheless, the role of AVP has not been entirely clarified. Objective: To investigate the mechanism by which AVP deficiency (by NIL) and desmopressin (DP, a synthetic analog of AVP) affects the development of the clinical signs, the immune response and gene expression profile in the EAE. Methods: Female Lewis rats were divided into intact control (IC), EAE immunized, NIL and NIL treated with desmopressin (NIL+DP). Except the IC, the remaining groups were immunized for EAE. The EAE was induced by encephalitogen subcutaneous injection. Animals were sacrificed at the peak of the disease (15 days after immunization). EAE clinical signs, cytokine serum profiles (IL‐17A, IL‐4, IL‐2, IL‐10, IL‐6, TNF‐α and INF‐γ) (flow cytometry) and spleen gene expression profile (microarray) were evaluated. DP treatment started 3 days before immunization. Results: As compared with the EAE group, NIL animals developed just a mild clinical signs of EAE and significant decreased IFN‐γ and IL‐17 levels. NIL+DP treated animals restored its susceptibility to EAE clinical signs, whereas no‐significant differences on cytokine levels occurred. Significant differences in gene expression profile among groups were evident; in the NIL group the expression pattern of the TGF‐β pathway was down‐regulated as compared with the EAE group, whereas in the NIL+DP group the same genes were up‐regulated. Conclusions: Findings add novel data indicating that directly AVP plays a crucial role in regulating the immune responses and suggests that AVP receptor blockers may be used for the MS treatment and possibly autoimmune diseases and other inflammatory processes. Support or Funding Information Supported by UAA‐PIFF14‐1 and CONACYT‐221262 (AQS). México. VVB: CONACT Doctoral scholarship. NMS: CONACYT post doctoral Fellow. México. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Open Access

    Transcriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease

    by N. Macías-Segura, J. E. Castañeda-Delgado, Y. Bastian, D. Santiago-Algarra, J. D. Castillo-Ortiz, A. L. Alemán-Navarro, E. Jaime-Sánchez, M. Gomez-Moreno, C. A. Saucedo-Toral, Edgar E. Lara-Ramírez, et al.

    Little is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed. Whole blood total RNA was obtained from non-treated early RA patients with 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways. The presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.


  • Open Access

    Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production

    by Julio E. Castañeda-Delgado, Yadira Bastián-Hernandez, Noe Macias-Segura, David Santiago-Algarra, Jose D. Castillo-Ortiz, Ana L. Alemán-Navarro, Pedro Martínez-Tejada, Leonor Enciso-Moreno, Yolanda Garcia-De Lira, Diana Olguín-Calderón, et al.

    Rheumatoid arthritis is an inflammatory debilitating disease that affects the joints in the early and productive phases of an individual’s life. Several cytokines have been linked to the disease pathogenesis and are known to contribute to the inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the pathogenesis of the disease has been already described as well as the identity of the genes that are regulated by this molecule, which are collectively known as the type I IFN signature. These genes have several functions associated to apoptosis, transcriptional regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. The present article evaluates the expression of the IFN signature in different stages of disease and their correlation with the levels of antibodies against citrullinated proteins (ACPA) and carbamylated proteins (Anti-CarP). Methods: Samples from individuals with early and established RA, high risk individuals (ACPA+ and ACPA-) and healthy controls were recruited at “Unidad de Artritis y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP determinations were made according to previously described protocols. RNA was isolated and purity and integrity determined according to RIN > 6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs of the type I IFN signature. Relative gene expression was calculated according to (Livak and Schmitgen). Results: Significant differences in gene expression were identified when comparing the different groups for MXA and MXB (p<0.05), also when comparing established RA and ACPA- in both IFIT 1 and G15. Increased expression of ISG15 was identified (p<0.05) and a clear tendency toward increase was identified for HERC5. EPSTRI1, IFI6 and IFI35 were found to be elevated in the cRA and eRA respectively (p<0.05). Significant correlations were identified for the IFN signature genes with the levels of ACPA and Anti-CarP (p<0.05). Conclusion: Our data confirms previous observations in the role of IFN signature and the pathogenesis of RA. Also, we provide evidence of an association between IFN-signature genes (that regulate Th2 cells and B cell proliferation) with the levels Anti-CarP and ACPA autoantibodies.


  • Transcriptional profiles discriminate patients with pulmonary tuberculosis from non-tuberculous individuals depending on the presence of non-insulin diabetes mellitus

    by Carmen J. Serrano, Betzaida Cuevas-Córdoba, Noé Macías-Segura, Rosa Angélica González-Curiel, Víctor Yordani Martínez-Balderas, Leonor Enciso-Moreno, Peter Small, Rogelio Hernández-Pando, José Antonio Enciso-Moreno


  • Associated Risk Factors for Latent Tuberculosis Infection in Subjects with Diabetes

    by Gerardo Martínez-Aguilar, Carmen J. Serrano, Julio Enrique Castañeda-Delgado, Noé Macías-Segura, Nicolás Hernández-Delgadillo, Leonor Enciso-Moreno, Yolanda García de Lira, Ema Valenzuela-Méndez, Benjamín Gándara-Jasso, Joel Correa-Chacón, et al.


  • Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus

    by Irma Gonzalez-Curiel, Julio Castañeda-Delgado, Nallely Lopez-Lopez, Zaida Araujo, Rogelio Hernandez-Pando, Benjamin Gandara-Jasso, Noe Macias-Segura, Antonio Enciso-Moreno, Bruno Rivas-Santiago